Loading…
Advances, challenges, and future directions in the clinical translation of ECM biomaterials for regenerative medicine applications
[Display omitted] Extracellular Matrix (ECM) scaffolds and biomaterials have been widely used for decades across a variety of diverse clinical applications and have been implanted in millions of patients worldwide. ECM-based biomaterials have been especially successful in soft tissue repair applicat...
Saved in:
Published in: | Advanced drug delivery reviews 2024-08, Vol.211, p.115347, Article 115347 |
---|---|
Main Authors: | , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | cdi_FETCH-LOGICAL-c237t-605fcf59c89c280a2e52b19c05eeb27a5393cb1a6656886ff835d3242385e88d3 |
container_end_page | |
container_issue | |
container_start_page | 115347 |
container_title | Advanced drug delivery reviews |
container_volume | 211 |
creator | Capella-Monsonís, Héctor Crum, Raphael J. Hussey, George S. Badylak, Stephen F. |
description | [Display omitted]
Extracellular Matrix (ECM) scaffolds and biomaterials have been widely used for decades across a variety of diverse clinical applications and have been implanted in millions of patients worldwide. ECM-based biomaterials have been especially successful in soft tissue repair applications but their utility in other clinical applications such as for regeneration of bone or neural tissue is less well understood. The beneficial healing outcome with the use of ECM biomaterials is the result of their biocompatibility, their biophysical properties and their ability to modify cell behavior after injury. As a consequence of successful clinical outcomes, there has been motivation for the development of next-generation formulations of ECM materials ranging from hydrogels, bioinks, powders, to whole organ or tissue scaffolds. The continued development of novel ECM formulations as well as active research interest in these materials ensures a wealth of possibilities for future clinical translation and innovation in regenerative medicine. The clinical translation of next generation formulations ECM scaffolds faces predictable challenges such as manufacturing, manageable regulatory pathways, surgical implantation, and the cost required to address these challenges. The current status of ECM-based biomaterials, including clinical translation, novel formulations and therapies currently under development, and the challenges that limit clinical translation of ECM biomaterials are reviewed herein. |
doi_str_mv | 10.1016/j.addr.2024.115347 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3065984523</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0169409X24001698</els_id><sourcerecordid>3065984523</sourcerecordid><originalsourceid>FETCH-LOGICAL-c237t-605fcf59c89c280a2e52b19c05eeb27a5393cb1a6656886ff835d3242385e88d3</originalsourceid><addsrcrecordid>eNp9kMtq3DAUQEVoSSaPH8iiaNlFPdXDsmXoJgxJWkjoJoHshCxdJRo08lSyB7rtl1eO0y6z0gWde-AehC4pWVNCm6_btbY2rRlh9ZpSwev2CK2obFklWVd_QKsCdVVNuqcTdJrzlhDK2oYcoxMuZV0TIlboz5U96Gggf8HmRYcA8XmedbTYTeOUAFufwIx-iBn7iMcXwCb46I0OeEw65qDnTzw4fL25x70fdnqE5HXI2A0JJ3iGCKlAB8A7sN74CFjv96EoXrXn6KMrNFy8vWfo8eb6YfO9uvt5-2NzdVcZxtuxaohwxonOyM4wSTQDwXraGSIAetZqwTtueqqbRjRSNs5JLixnNeNSgJSWn6HPi3efhl8T5FHtfDYQgo4wTFlx0ohO1oLxgrIFNWnIOYFT--R3Ov1WlKi5vdqqub2a26ulfVn69Oaf-nLo_5V_sQvwbQGgXHnwkFQ2Hkr8JbGyg3_P_xey25bb</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3065984523</pqid></control><display><type>article</type><title>Advances, challenges, and future directions in the clinical translation of ECM biomaterials for regenerative medicine applications</title><source>ScienceDirect Freedom Collection</source><creator>Capella-Monsonís, Héctor ; Crum, Raphael J. ; Hussey, George S. ; Badylak, Stephen F.</creator><creatorcontrib>Capella-Monsonís, Héctor ; Crum, Raphael J. ; Hussey, George S. ; Badylak, Stephen F.</creatorcontrib><description>[Display omitted]
Extracellular Matrix (ECM) scaffolds and biomaterials have been widely used for decades across a variety of diverse clinical applications and have been implanted in millions of patients worldwide. ECM-based biomaterials have been especially successful in soft tissue repair applications but their utility in other clinical applications such as for regeneration of bone or neural tissue is less well understood. The beneficial healing outcome with the use of ECM biomaterials is the result of their biocompatibility, their biophysical properties and their ability to modify cell behavior after injury. As a consequence of successful clinical outcomes, there has been motivation for the development of next-generation formulations of ECM materials ranging from hydrogels, bioinks, powders, to whole organ or tissue scaffolds. The continued development of novel ECM formulations as well as active research interest in these materials ensures a wealth of possibilities for future clinical translation and innovation in regenerative medicine. The clinical translation of next generation formulations ECM scaffolds faces predictable challenges such as manufacturing, manageable regulatory pathways, surgical implantation, and the cost required to address these challenges. The current status of ECM-based biomaterials, including clinical translation, novel formulations and therapies currently under development, and the challenges that limit clinical translation of ECM biomaterials are reviewed herein.</description><identifier>ISSN: 0169-409X</identifier><identifier>ISSN: 1872-8294</identifier><identifier>EISSN: 1872-8294</identifier><identifier>DOI: 10.1016/j.addr.2024.115347</identifier><identifier>PMID: 38844005</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Advancing ECM-based therapies ; ECM scaffolds ; Regenerative medicine ; Translational development ; Translational science</subject><ispartof>Advanced drug delivery reviews, 2024-08, Vol.211, p.115347, Article 115347</ispartof><rights>2024 Elsevier B.V.</rights><rights>Copyright © 2024 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c237t-605fcf59c89c280a2e52b19c05eeb27a5393cb1a6656886ff835d3242385e88d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38844005$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Capella-Monsonís, Héctor</creatorcontrib><creatorcontrib>Crum, Raphael J.</creatorcontrib><creatorcontrib>Hussey, George S.</creatorcontrib><creatorcontrib>Badylak, Stephen F.</creatorcontrib><title>Advances, challenges, and future directions in the clinical translation of ECM biomaterials for regenerative medicine applications</title><title>Advanced drug delivery reviews</title><addtitle>Adv Drug Deliv Rev</addtitle><description>[Display omitted]
Extracellular Matrix (ECM) scaffolds and biomaterials have been widely used for decades across a variety of diverse clinical applications and have been implanted in millions of patients worldwide. ECM-based biomaterials have been especially successful in soft tissue repair applications but their utility in other clinical applications such as for regeneration of bone or neural tissue is less well understood. The beneficial healing outcome with the use of ECM biomaterials is the result of their biocompatibility, their biophysical properties and their ability to modify cell behavior after injury. As a consequence of successful clinical outcomes, there has been motivation for the development of next-generation formulations of ECM materials ranging from hydrogels, bioinks, powders, to whole organ or tissue scaffolds. The continued development of novel ECM formulations as well as active research interest in these materials ensures a wealth of possibilities for future clinical translation and innovation in regenerative medicine. The clinical translation of next generation formulations ECM scaffolds faces predictable challenges such as manufacturing, manageable regulatory pathways, surgical implantation, and the cost required to address these challenges. The current status of ECM-based biomaterials, including clinical translation, novel formulations and therapies currently under development, and the challenges that limit clinical translation of ECM biomaterials are reviewed herein.</description><subject>Advancing ECM-based therapies</subject><subject>ECM scaffolds</subject><subject>Regenerative medicine</subject><subject>Translational development</subject><subject>Translational science</subject><issn>0169-409X</issn><issn>1872-8294</issn><issn>1872-8294</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9kMtq3DAUQEVoSSaPH8iiaNlFPdXDsmXoJgxJWkjoJoHshCxdJRo08lSyB7rtl1eO0y6z0gWde-AehC4pWVNCm6_btbY2rRlh9ZpSwev2CK2obFklWVd_QKsCdVVNuqcTdJrzlhDK2oYcoxMuZV0TIlboz5U96Gggf8HmRYcA8XmedbTYTeOUAFufwIx-iBn7iMcXwCb46I0OeEw65qDnTzw4fL25x70fdnqE5HXI2A0JJ3iGCKlAB8A7sN74CFjv96EoXrXn6KMrNFy8vWfo8eb6YfO9uvt5-2NzdVcZxtuxaohwxonOyM4wSTQDwXraGSIAetZqwTtueqqbRjRSNs5JLixnNeNSgJSWn6HPi3efhl8T5FHtfDYQgo4wTFlx0ohO1oLxgrIFNWnIOYFT--R3Ov1WlKi5vdqqub2a26ulfVn69Oaf-nLo_5V_sQvwbQGgXHnwkFQ2Hkr8JbGyg3_P_xey25bb</recordid><startdate>20240801</startdate><enddate>20240801</enddate><creator>Capella-Monsonís, Héctor</creator><creator>Crum, Raphael J.</creator><creator>Hussey, George S.</creator><creator>Badylak, Stephen F.</creator><general>Elsevier B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20240801</creationdate><title>Advances, challenges, and future directions in the clinical translation of ECM biomaterials for regenerative medicine applications</title><author>Capella-Monsonís, Héctor ; Crum, Raphael J. ; Hussey, George S. ; Badylak, Stephen F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c237t-605fcf59c89c280a2e52b19c05eeb27a5393cb1a6656886ff835d3242385e88d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Advancing ECM-based therapies</topic><topic>ECM scaffolds</topic><topic>Regenerative medicine</topic><topic>Translational development</topic><topic>Translational science</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Capella-Monsonís, Héctor</creatorcontrib><creatorcontrib>Crum, Raphael J.</creatorcontrib><creatorcontrib>Hussey, George S.</creatorcontrib><creatorcontrib>Badylak, Stephen F.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Advanced drug delivery reviews</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Capella-Monsonís, Héctor</au><au>Crum, Raphael J.</au><au>Hussey, George S.</au><au>Badylak, Stephen F.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Advances, challenges, and future directions in the clinical translation of ECM biomaterials for regenerative medicine applications</atitle><jtitle>Advanced drug delivery reviews</jtitle><addtitle>Adv Drug Deliv Rev</addtitle><date>2024-08-01</date><risdate>2024</risdate><volume>211</volume><spage>115347</spage><pages>115347-</pages><artnum>115347</artnum><issn>0169-409X</issn><issn>1872-8294</issn><eissn>1872-8294</eissn><abstract>[Display omitted]
Extracellular Matrix (ECM) scaffolds and biomaterials have been widely used for decades across a variety of diverse clinical applications and have been implanted in millions of patients worldwide. ECM-based biomaterials have been especially successful in soft tissue repair applications but their utility in other clinical applications such as for regeneration of bone or neural tissue is less well understood. The beneficial healing outcome with the use of ECM biomaterials is the result of their biocompatibility, their biophysical properties and their ability to modify cell behavior after injury. As a consequence of successful clinical outcomes, there has been motivation for the development of next-generation formulations of ECM materials ranging from hydrogels, bioinks, powders, to whole organ or tissue scaffolds. The continued development of novel ECM formulations as well as active research interest in these materials ensures a wealth of possibilities for future clinical translation and innovation in regenerative medicine. The clinical translation of next generation formulations ECM scaffolds faces predictable challenges such as manufacturing, manageable regulatory pathways, surgical implantation, and the cost required to address these challenges. The current status of ECM-based biomaterials, including clinical translation, novel formulations and therapies currently under development, and the challenges that limit clinical translation of ECM biomaterials are reviewed herein.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>38844005</pmid><doi>10.1016/j.addr.2024.115347</doi></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0169-409X |
ispartof | Advanced drug delivery reviews, 2024-08, Vol.211, p.115347, Article 115347 |
issn | 0169-409X 1872-8294 1872-8294 |
language | eng |
recordid | cdi_proquest_miscellaneous_3065984523 |
source | ScienceDirect Freedom Collection |
subjects | Advancing ECM-based therapies ECM scaffolds Regenerative medicine Translational development Translational science |
title | Advances, challenges, and future directions in the clinical translation of ECM biomaterials for regenerative medicine applications |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T11%3A59%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Advances,%20challenges,%20and%20future%20directions%20in%20the%20clinical%20translation%20of%20ECM%20biomaterials%20for%20regenerative%20medicine%20applications&rft.jtitle=Advanced%20drug%20delivery%20reviews&rft.au=Capella-Monson%C3%ADs,%20H%C3%A9ctor&rft.date=2024-08-01&rft.volume=211&rft.spage=115347&rft.pages=115347-&rft.artnum=115347&rft.issn=0169-409X&rft.eissn=1872-8294&rft_id=info:doi/10.1016/j.addr.2024.115347&rft_dat=%3Cproquest_cross%3E3065984523%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c237t-605fcf59c89c280a2e52b19c05eeb27a5393cb1a6656886ff835d3242385e88d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3065984523&rft_id=info:pmid/38844005&rfr_iscdi=true |